SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Novo Nordisk Says CagriSema Analyses Show 25% Mean Weight Loss

Novo Nordisk said analyses from a Phase 3 study of its investigational CagriSema treatment showed 25% mean weight loss.

NVO

Related stories